Mesoblast targets AMD and retinopathy

By Dylan Bushell-Embling
Thursday, 10 July, 2008

Mesoblast [ASX: MSB] today released results from its sister company Angioblast's pre-clinical trials into using adult stem cells to treat ocular diseases association with abnormal blood vessels.

Trials involving 42 non-human primates indicates that an injection of Mesoblast's proprietary adult stem cells combined with an anti-VEGF agent were able to reduce the number of leaking blood vessels - a major cause of ocular disease - more effectively than using an anti-VEGF agent alone.

The combination also reduced the number of subsequent anti-VEGF injections required in the primates.

The results of this trial will comprise part of the company's IND application to the US FDA.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd